Impact of proposed US tariffs on pharmaceutical FDI in Canada, Mexico, China and Europe
The pharmaceutical industry is bracing for potentially major disruptions following US President Donald Trump’s announcement of new tariffs on imported goods - 25% on Canada and Mexico, both paused for 30 days, and 10% on China - with the potential for expansion to additional countries.
The pharmaceutical industry is bracing for potentially major disruptions following US President Donald Trump’s announcement of new tariffs on imported goods - 25% on Canada and Mexico, both paused for 30 days, and 10% on China - with the potential for expansion to additional countries.
What's Your Reaction?
